RATIONALE AND OBJECTIVES: To investigate for differences in metabolic concentrations and ratios between patients with systemic lupus erythematosus (SLE) without (group SLE) and those with neurological symptoms (group NPSLE) compared to a healthy control (group HC) in three normal-appearing brain regions: the frontal white matter, right insula (RI), and occipital gray matter and whether changes in any of the metabolites or metabolic ratios are correlated to disease activity and other clinical parameters. MATERIALS AND METHODS: Twenty patients with SLE (18 women and 2 men, age range 23.4-64.6 years, mean age 43.9 years), 23 NPSLE patients (23 women, age range 23.7-69.8 years, mean age 42.4 years), and 21 HC (19 women and 2 men, age range 21.0-65.7 years, mean age 43.4 years) were included. All subjects had conventional brain magnetic resonance imaging and (1)H single-voxel spectroscopy, clinical assessment, and laboratory testing. RESULTS: NPSLE patients had significantly reduced N-acetylaspartate (NAA)/creatine compared to HC (P = .02) and SLE patients (P = .01) in the RI. Lower glutamine/creatine levels were also detected in RI in both patient groups and in frontal white matter in NPSLE patients compared to HC (P = .01, P = .02). NAA/Cr ratio in the RI was significantly negatively correlated with the Systemic Lupus Erythematosus Disease Activity Index (r = -0.41; P = .008), and patients with active SLE symptoms also had a trend toward lower NAA/creatine ratios (1.02 vs 1.12; P = .07). CONCLUSIONS: The present data support previous findings of abnormal metabolic changes in normal-appearing regions in the brain of both SLE and NPSLE patients and raise the possibility that especially NAA, glutamine, and glutamate may be additional biomarkers for cerebral disease activity in SLE patients as these early metabolic changes occur in the brain of SLE patients before neurologic and imaging manifestations become apparent.
RATIONALE AND OBJECTIVES: To investigate for differences in metabolic concentrations and ratios between patients with systemic lupus erythematosus (SLE) without (group SLE) and those with neurological symptoms (group NPSLE) compared to a healthy control (group HC) in three normal-appearing brain regions: the frontal white matter, right insula (RI), and occipital gray matter and whether changes in any of the metabolites or metabolic ratios are correlated to disease activity and other clinical parameters. MATERIALS AND METHODS: Twenty patients with SLE (18 women and 2 men, age range 23.4-64.6 years, mean age 43.9 years), 23 NPSLE patients (23 women, age range 23.7-69.8 years, mean age 42.4 years), and 21 HC (19 women and 2 men, age range 21.0-65.7 years, mean age 43.4 years) were included. All subjects had conventional brain magnetic resonance imaging and (1)H single-voxel spectroscopy, clinical assessment, and laboratory testing. RESULTS: NPSLE patients had significantly reduced N-acetylaspartate (NAA)/creatine compared to HC (P = .02) and SLEpatients (P = .01) in the RI. Lower glutamine/creatine levels were also detected in RI in both patient groups and in frontal white matter in NPSLE patients compared to HC (P = .01, P = .02). NAA/Cr ratio in the RI was significantly negatively correlated with the Systemic Lupus Erythematosus Disease Activity Index (r = -0.41; P = .008), and patients with active SLE symptoms also had a trend toward lower NAA/creatine ratios (1.02 vs 1.12; P = .07). CONCLUSIONS: The present data support previous findings of abnormal metabolic changes in normal-appearing regions in the brain of both SLE and NPSLE patients and raise the possibility that especially NAA, glutamine, and glutamate may be additional biomarkers for cerebral disease activity in SLEpatients as these early metabolic changes occur in the brain of SLEpatients before neurologic and imaging manifestations become apparent.
Authors: Bart J Emmer; Matthias J van Osch; Ona Wu; Gerda M Steup-Beekman; Stefan C Steens; Tom W Huizinga; Mark A van Buchem; Jeroen van der Grond Journal: J Magn Reson Imaging Date: 2010-08 Impact factor: 4.813
Authors: Page I Wang; Patricia C Cagnoli; William J McCune; Tobias Schmidt-Wilcke; Suzan E Lowe; Courtney C Graft; Stephen S Gebarski; Thomas L Chenevert; Shokoufeh Khalatbari; James D Myles; Kuanwong Watcharotone; Paul Cronin; Pia C Sundgren Journal: Acad Radiol Date: 2012-05-17 Impact factor: 3.173
Authors: Charles M Gasparovic; Carlos A Roldan; Wilmer L Sibbitt; Clifford R Qualls; Paul G Mullins; Janeen M Sharrar; J Jeremy Yamamoto; H Jeremy Bockholt Journal: J Rheumatol Date: 2010-06-15 Impact factor: 4.666
Authors: R L Brey; S L Holliday; A R Saklad; M G Navarrete; D Hermosillo-Romo; C L Stallworth; C R Valdez; A Escalante; I del Rincón; G Gronseth; C B Rhine; P Padilla; D McGlasson Journal: Neurology Date: 2002-04-23 Impact factor: 9.910
Authors: Gerda M Steup-Beekman; Elisabeth J M Zirkzee; Danielle Cohen; Bastiaan M A Gahrmann; Bart J Emmer; Stefan C A Steens; Eduard L E M Bollen; Mark A van Buchem; Tom W J Huizinga Journal: Ann Rheum Dis Date: 2012-12-19 Impact factor: 19.103
Authors: Michelle Petri; Mohammad Naqibuddin; Kathryn A Carson; Daniel J Wallace; Michael H Weisman; Stephen L Holliday; Margaret Sampedro; Shalini Narayana; Peter T Fox; Crystal Franklin; Patricia A Padilla; Robin L Brey Journal: J Rheumatol Date: 2008-09-15 Impact factor: 4.666
Authors: Johan Mårtensson; Theodor Rumetshofer; Jessika Nystedt; Jimmy Lätt; Petra Nilsson; Anders Bengtsson; Andreas Jönsen; Pia C Sundgren Journal: Brain Sci Date: 2021-04-16
Authors: Tobias Schmidt-Wilcke; Patricia Cagnoli; Page Wang; Thomas Schultz; Anne Lotz; William J Mccune; Pia C Sundgren Journal: Neuroimage Clin Date: 2014-07-10 Impact factor: 4.881